atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder- A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three months
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant depression patients around YE’24
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual SummitNEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that Srinivas Rao, M.D., Ph.D., the Company’s Co-founder and Co-CEO, is scheduled to participate in the 2024 Maxim Healthcare Virtual Summit taking place from October 15 – 17, 2024. Details of the company’s participation:
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company’s participation:
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE’24
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced positive preliminary results from the Phase 1b trial of VLS-01, its proprietary oral transmucosal film formulation of N,N-dimethyltryptamine (DMT) that is applied to the buccal surface.
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth ConferenceNEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston, MA from August 13-15, 2024. Details of the company’s participation:
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives ConferenceNEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company’s participation:
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2aNEW YORK and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced an update on Beckley Psytech’s Phase 1/2a trial of ELE-101 (NCT05434156) for people living with MDD, with initial results from Phase 1 and the dosing of the first patients in the Phase 2a part of the study.
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare ConferenceNEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the Jefferies Global Healthcare Conference being held from June 4-6, 2024.
atai Life Sciences Strengthens Board with Appointment of Two New Independent DirectorsNEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements.
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate UpdatesNEW YORK and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced first quarter 2024 financial results, provided corporate updates and announced a transition in its leadership.
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant DepressionNEW YORK and BERLIN, April 24, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the first patient has been dosed in Part 2 of Beckley Psytech’s Phase 2a study, evaluating BPL-003 (intranasal 5-MeO-DMT) in patients living with Treatment Resistant Depression (TRD).
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of PsychopharmacologyNEW YORK and BERLIN, April 17, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the publication of the Phase 1 results of BPL-003, Beckley Psytech’s novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT, in The Journal of Psychopharmacology.
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical HighlightsNEW YORK and BERLIN, March 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced fourth quarter and full year 2023 financial results and provided corporate and clinical highlights.
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01NEW YORK and BERLIN, March 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the first healthy participant has been dosed in the Phase 1b trial of VLS-01, an oral transmucosal film (OTF) formulation of N,N-dimethyltryptamine (DMT).
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care ConferenceNEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that management will participate in a panel discussion at the TD Cowen conference in Boston, MA, at 12:50pm ET on March 4, 2024.
atai Life Sciences Appoints Anne Johnson as Chief Financial OfficerNEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”) today announced that Anne Johnson, the Company’s interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO).
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration PsychedelicsNEW YORK and BERLIN, Jan. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)NEW YORK and BERLIN, Jan. 02, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (
NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced positive results from its Phase 1 study evaluating orally administered EMP-01, the R-enantiomer of MDMA (3,4-methylenedioxy-methamphetamine).
5 Biotech stocks tapping into unmet mental health treatment needsHere are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments.
